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Section of General Internal Medicine, Department of Internal Medicine, Yale University, School 
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 People who smoke cigarettes are 2-4 times more likely to have a stroke1 and 2-5 times 
more likely to have a myocardial infarction2 compared with people who do not smoke. On a 
population level, it is estimated that smoking accounts for 33% of all cardiovascular deaths.3  
Fortunately, quitting smoking can rapidly normalize risk. After an MI, smoking cessation 
reduces the risk of recurrent coronary events to the level of a never-smoker's after 3 years.4 
While the benefits of smoking cessation in patients with cardiovascular disease are well-known, 
the benefits of smoking cessation after stroke have never been adequately examined and remain 
unquantified. In this research, we tested the hypothesis that smoking cessation after an ischemic 
stroke or transient ischemic attack (TIA) improves outcome, compared to continued smoking. 
We conducted a prospective observational cohort study of 1072 men and women who were 
current cigarette smokers at the time they were enrolled in the Insulin Resistance Intervention 
after Stroke (IRIS) trial. The IRIS trial was conducted during 2005-2015 to test the effectiveness 
of pioglitazone, compared with placebo, for prevention of stroke or MI among non-diabetic 
patients with a recent qualifying stroke or TIA; the main finding was that pioglitazone 
significantly reduced the risk of subsequent stroke or MI.5 A tobacco use history was obtained at 
baseline and updated during annual interviews. Cox regression models were used to estimate the 
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differences in rates of stroke, MI, or death between quitters and continuing smokers after 4.8 
years of IRIS participation. Pre-specified adjustment variables were age, sex, stroke [vs. TIA] as 
index event, prior history of stroke, history of hypertension, history of coronary artery disease, 
systolic blood pressure, diastolic blood pressure, and pioglitazone treatment. By the time of 
randomization, 450 (42%) patients had quit smoking. Among quitters, the 5-year risk of stroke, 
MI, or death was 15.7%, compared to 22.6% for patients who continued to smoke (adjusted 
hazard ratio, 0.66; 95% confidence interval, 0.48-0.90). Cessation of cigarette smoking after an 
ischemic stroke or TIA was associated with significant health benefits over 4.8 years in the IRIS 
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 Stroke is the fifth leading cause of death in the US and the second leading cause of death 
worldwide.6 Tobacco use results in a strong, dose-dependent increase in stroke risk7,8 and is 
estimated to be responsible for 12-15% of all stroke events.9,10 Smoking is therefore a leading 
preventable cause of stroke.  Other well-documented harms of smoking include coronary and 
peripheral artery disease, chronic obstructive pulmonary disease, and cancer of the lung and 
urinary bladder. Despite decades of research on these adverse effects, 15% of adults in the US 
currently smoke cigarettes.11 Use peaks at 21% for persons 25-44 years of age and falls to 7.9% 
after age 65 years.12 Recent AHA guidelines for primary prevention of stroke include a Class I 
recommendation for abstinence from smoking.13 Although never smoking is undoubtedly the 
best strategy for primary prevention of stroke and other smoking-related harms, smoking 
cessation is increasingly recognized as a powerful intervention that can rapidly diminish risk for 
stroke or MI, and over time decrease a current smoker’s risk to near that of a never-smoker’s.14-18 
 Patients who have already experienced an ischemic stroke or TIA are at increased risk for 
future cardiovascular events, and therefore represent a high-risk group for whom interventions 
are likely to have a large impact.19 Smoking cessation for these patients is a logical choice for 
secondary prevention, but there are limited data quantifying the effect of cessation compared to 
continued smoking after an ischemic stroke or TIA. AHA guidelines for secondary prevention 
also include a Class 1 recommendation for abstinence or (if applicable) cessation from smoking 
after an ischemic stroke or TIA, but the level of evidence is only a C, meaning the 
recommendation is based on very limited populations evaluated, consensus opinions of experts, 
case studies, and/or accepted standard of care.19  
 7 
 
 The Class I recommendation for cessation or abstinence from smoking after a first stroke 
or TIA is primarily based on research from stroke-free populations showing that smoking 
cessation in midlife or even late-life is associated with rapid return toward normal of risk for 
vascular events.20 There is no well-controlled study quantifying the risk reduction in patients 
who stop smoking after a stroke or TIA. By comparison, there is a substantial body of literature 
demonstrating the benefits of smoking cessation for patients with CAD21-23 or post myocardial 
infarction.4,24 After an MI, smoking cessation reduces the risk of recurrent coronary events to the 
level of a never-smoker's after 3 years4 and the risk of mortality by 46% over 2-10 years. 
Smoking cessation for patients with CAD is associated with a 36% reduction in mortality over 3-
7 years.22 Smoking cessation is a uniquely powerful intervention in secondary prevention of 
cardiovascular disease. By analogy, it is possible that smoking cessation is a uniquely powerful 
intervention in secondary prevention of stroke. Quantifying this risk reduction could be very 
helpful in guiding the efforts of stroke patients and their clinicians in reducing their risk of a 
future cardiovascular event. Among patients with a first-ever stroke, one third (32-39%) are 
current smokers, and less than half (22-43%) of these current smokers are able to quit smoking 
after their stroke.25,26 Among those who do quit, many may relapse. One study showed that 43% 
of smokers initially quit smoking after a stroke, whereas only 28% were still abstinent after 6 
months.26 Quantifying the health benefits of quitting smoking after a stroke may help patients 







STATEMENT OF THE PURPOSE 
The purpose of this study was to test the hypothesis that smoking cessation after an ischemic 
stroke or TIA will improve outcome relative to continued smoking. 
 
The primary outcome was a composite of nonfatal stroke, nonfatal MI, or death. Secondary 
outcomes included nonfatal stroke alone, nonfatal MI alone, and all-cause death alone. 
 
METHODS 
Contribution of the student 
The present study was a secondary analysis of the Insulin Resistance Intervention after Stroke 
(IRIS) dataset that was not pre-specified in the trial protocol. The idea for the study emerged 
from a conversation between the student and her mentor, Dr. Walter Kernan, on the general 
problem of over-diagnosis of chronic conditions. When it became apparent that the IRIS trial did 
not include data that would allow for an analysis of over-diagnosis in stroke, the student and 
mentor turned to the student’s interest in psychiatry and addiction. They realized the IRIS trial 
data set was distinctive in containing detailed information on patients' tobacco use over 5 years 
of follow-up. The student then conducted a literature search and discovered a dearth of reliable 
information about the effects of smoking cessation after a stroke or TIA. She drafted a set of 
research aims and then worked in collaboration with Dr. Kernan and Dr. Catherine Viscoli to 
design the analyses and interpret the results. At every step, the student’s initial proposals for 
methods, analysis, and interpretation drove the research and were used as the basis for team 
discussions. The student wrote the first draft of the manuscript, and revised it in collaboration 
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with Drs. Kernan and Viscoli. Description of methods for the original IRIS trial are based on 
Viscoli et al. 2014 and Tables 1 and 2 are modified from Viscoli et al. 2014, with permission 




The IRIS trial (www.clinicaltrials.gov NCT00091949) was an investigator-initiated, 
international, multicenter, randomized, double-blind, placebo-controlled study in 3,876 
nondiabetic patients with insulin resistance and a recent ischemic stroke or TIA. The objective 
was to evaluate whether pioglitazone, an insulin-sensitizing drug of the thiazolidinedione (TZD) 
class, when initiated less than 6 months after an ischemic stroke or TIA, reduces the incidence of 
subsequent stroke and MI. The main finding was that pioglitazone reduced the risk of subsequent 
stroke or MI. 
 
The objective of this secondary analysis of the IRIS trial was to evaluate whether smoking 
cessation after an ischemic stroke or TIA is associated with a lower incidence of subsequent 
nonfatal stroke, nonfatal MI, or all-cause death, compared with continued smoking.  
 
Study population 
The study population for this thesis comprised patients who were current cigarette smokers at the 
time of the ischemic stroke or TIA that qualified them for subsequent enrollment in the IRIS 
trial. Inclusion and exclusion criteria for the IRIS trial are shown in Table 1. Eligible participants 
were ≥40 years of age, had an ischemic stroke or TIA within the past six months, and had no 
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prior or current diagnosis of diabetes. An ischemic stroke was defined by focal neurologic 
deficits persisting for ≥24 hours and/or a new area of infarction on brain imaging in an 
appropriate location. Patients who had isolated symptoms affecting only one eye were required 
to have imaging evidence of a new ischemic brain abnormality in an appropriate location. After 
recruitment began in January 2005, the protocol was changed in November 2005 to allow 
enrollment of participants with nonvalvular atrial fibrillation. In 2006, eligibility was further 
expanded to include patients with TIAs. A TIA was defined as an acute neurologic change 
attributable to brain ischemia that lasted ≥10 minutes but <24 hours, without imaging evidence 
of new cerebral infarction. To enroll patients who likely had a vascular etiology for their 
symptoms, eligible TIA deficits were limited to hemiplegia or hemiparesis, monoplegia or 
monoparesis, or a language disturbance besides isolated dysarthria.28 In 2007, eligibility was 
expanded to include patients with non-focal neurological symptoms (e.g., dizziness, confusion, 
and headache) lasting ≥24 hours and accompanied by a focal abnormality detected on diffusion 
weighted magnetic resonance imaging (MRI). 
 
Patients with insulin resistance were identified by a value > 3.0 on the Homeostasis Model 
Assessment–Insulin Resistance (HOMA-IR) (calculated as [fasting insulin, µU/mL x fasting 
glucose, mmol/L]/22.520).  Results from the HOMA-IR are closely associated with results of 
more complex tests of insulin sensitivity, as well as with glucose intolerance,29 progression to 
diabetes mellitus type II,30,31 metabolic syndrome,32 and cardiovascular disease.33,34 A HOMA-IR 
> 3.0 was selected as the diagnostic criterion for the IRIS trial because this value demarcates the 
top quartile of nondiabetic patients with insulin resistance in general populations.35 In 
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epidemiologic studies, this top quartile has increased risk for cardiovascular disease compared 
with the lower three quartiles.34  
 
Since TZD drugs are known to cause or exacerbate congestive heart failure (CHF), patients with 
New York Heart Association class 3 or 4 heart failure were excluded, although patients with 
class 2 CHF (i.e., symptomatic with moderate activity) and an ejection fraction ≥40% were 
initially eligible at US sites. Because pioglitazone can also cause edema, patients with advanced 
lower extremity edema were also excluded. 
  
In 2007, after new prescribing guidelines for pioglitazone were issued, patients with 
symptomatic CHF were no longer permitted to participate. In 2008, patients with any history of 
CHF were excluded. Other external developments during the trial led to several protocol changes 
to ensure the safety of participants and to conform with changing regulations. When IRIS began 
in 2005, there was no evidence to suggest a connection between pioglitazone treatment and 
bladder cancer in humans. Data from other trials subsequently emerged to suggest a possible 
imbalance of bladder cancer in pioglitazone-treated diabetic patients. The IRIS protocol was then 
revised in 2007 to exclude patients with a history of bladder cancer. In 2011, in response to an 
FDA advisory on the topic, patients with specific risk factors for bladder cancer, such as a 
history of pelvic radiation, cytoxan exposure, or uninvestigated macroscopic hematuria, were 






IRIS Trial Procedures  
Patients who provided informed consent for the IRIS trial attended a screening visit that included 
an interview (including smoking history), a physical examination, and fasting blood test (Table 
2). Because glucose metabolism may be altered immediately after a stroke,36 the screening test to 
measure HOMA-IR was conducted a minimum of 14 days after the index stroke or TIA. Blood 
samples were processed centrally by Esoterix Inc. (Cranford, NJ; Burlington, NC) or an affiliate 
laboratory. The Linco (St. Charles, MO) human insulin-specific radioimmunoassay (RIA) was 
used in North America and Australia to measure insulin concentrations in the blood. Because this 
assay was unavailable in Europe and Israel, the Linco animal serum-free enzyme-linked 
immunosorbent assay was used and results were converted to RIA values using an internal 
LINCO correlation equation (insulin RIA [µU/mL] = 1.1056 x (insulin enzyme-linked 
immunosorbent assay [ulU/mL]) + 2.1494).37 
 
Patients with HOMA-IR >3.0 who had no excluded conditions were randomly assigned in a 1:1 
ratio to initial treatment with either 15 mg pioglitazone tablet or placebo tablet daily by mouth. 
Placebo and active tablets were identical in both appearance and texture. Randomization was 
conducted using a random permuted block design with variable block sizes that were stratified 
by site. To hide the allocation sequence, randomization lists were kept only at the central 
pharmacy and the statistical center.37 
 
After month 4, participants were contacted every 4 months. Each year, in-person assessments 
were conducted that included a physical examination, Modified Mini-Mental State test,38 fasting 
blood test, and smoking status. Participants who survived the primary IRIS outcome stroke or MI 
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were maintained on study medication. The IRIS investigators monitored vascular risk factors, 
reported them to participants and their physicians annually, and advised participants to achieve 
their secondary prevention goals. However, providing standard secondary preventive care was 
the responsibility of each patient's personal physician.37 
 
Smoking history was assessed at screening when participants were asked when (if applicable) 
they started smoking cigarettes, and when (if applicable) they quit smoking. If they were current 
cigarette smokers, participants were asked how many cigarettes they smoked per day. At 
randomization and annually during follow up, participants were asked if they were current 
smokers. 
 
Participants were followed for 5 years or until the last scheduled contact that occurred before the 
end date of the trial (July 1, 2015), whichever came first.37 
 
Student Thesis Outcome  
The primary outcome for the IRIS trial was time to first occurrence of fatal or non-fatal stroke or 
fatal or non-fatal MI. However, the primary outcome for the student’s thesis was time to first 
occurrence of non-fatal stroke, non-fatal MI, or all-cause death. All-cause death was included in 
the student’s primary outcome, despite not being part of the primary outcome for the original 
IRIS trial, because of convincing data showing that cigarette smoking increases risk for all-cause 
death. Current smokers die at rates three times as high as never-smokers, from cancer, or from 




Primary and secondary outcomes for both the IRIS trial and the student's thesis are shown in 
Table 3. Clinical event committees for adjudicating neurology, cardiology, and endocrinology 
events were composed of a chairperson and ≥3 specialists. Two reviewers adjudicated each 
potential outcome, with a third reviewer added if necessary to reach a majority decision. All 
reviewers were blinded to treatment allocation and smoking status and received training in IRIS 
outcome criteria. Cause of death was classified by the blinded cardiology committee using 
documentation provided for each deceased participant, including hospital admission note, 
hospital discharge summary, or death certificate, if available. Specific categories for causes of 
death included stroke, MI, congestive heart failure, other cardiac, cancer, infection, other (with 
specific "other" cause recorded on form), and unknown. 
 
All incident cancers were reviewed and confirmed by a blinded oncologist to determine type and 
stage. Pathology data was required for confirmation of cancer by the oncology reviewer. In the 
current analysis, a death was attributed to cancer if the oncologist confirmed a diagnosis of 
cancer based on pathology data, and the cardiology outcome committee attributed the cause of 
death to cancer based on available clinical data. Deaths classified as due to cancer by the 
cardiology committee without confirming pathology data were classified as "other" cause of 
death. Cancer deaths were assigned a type of cancer based on the primary tumor type as 
determined by the oncology reviewer, including lung, colon, brain, pancreatic, bladder, prostate, 
and primary unknown. 
 
Safety outcomes of particular interest included heart failure, bone fracture, and bladder cancer. 
During the trial, several developments prompted modifications of the protocol and of the 
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informed consent document. In 2006, a randomized trial reported a higher rate of fractures in 
women receiving rosiglitazone, another TZD drug.39 In March 2007, the manufacturer of 
pioglitazone alerted health care providers to a similar finding after analyzing its clinical trial 
database. In April 2007, the IRIS informed consent was modified to describe this potential new 
risk of fracture. A query for fractures was added to interviews; already-enrolled participants were 
asked to complete a retrospective survey asking about fractures, and all participants were advised 
to follow standard recommendations to optimize bone health. The revised 2007 informed consent 
also described new information from clinical trials in humans suggesting an association between 
pioglitazone use and bladder cancer. In 2011, after several observational studies reported higher 
rates of bladder cancer in diabetic patients treated with pioglitazone40,41 the informed consent 
was again revised and the protocol modified to exclude participants with selected risk factors for 
bladder cancer. Enrolled participants who were determined to have those risk factors were 
removed from study medication.37 
 
Patient consents and standard protocol approvals 
Informed consent was signed by all participants. The study was approved in each participating 




The student’s thesis was designed as an observational analysis of previously-collected data in the 




Sample size and duration of enrollment 
The sample size for the original IRIS trial (N=3,136) was determined by a power analysis for its 
primary research aim. Because the enrollment rate fell below projections, in July 2007 the 
duration of enrollment was lengthened to achieve the original sample size. In February 2011, the 
Data Safety Monitoring Board (DSMB) recommended increasing person-years in the trial by 
further lengthening recruitment to June 2012 and follow-up to June 2015, based on the results of 
the first blinded interim analysis. In mid-2012, the DSMB allowed continued recruitment at 
selected high-recruiting sites. Recruitment was terminated on January 15, 2013 with a cohort of 
3,876 participants. The present study was a secondary analysis designed to use all the available 
data from the IRIS trial. 
 
Statistical analyses 
IRIS participants were classified according to smoking status at the time of randomization: (a) 
never smokers, (b) former smokers (i.e., stopped smoking prior to the index stroke or TIA event), 
(c) quitters (i.e., quit after the index event and not smoking at time of randomization), or (d) 
continuing smokers. The primary aim of our analysis was to compare the risk of the composite 
outcome of nonfatal stroke, nonfatal MI, or all-cause death in patients who quit smoking versus 
patients who continued to smoke after their index event. We also examined risk for the 
components of this outcome (i.e., stroke alone, MI alone, and all-cause mortality) and the 
incidence of cancer in quitters compared to continuing smokers. Participants without outcomes 
were censored at the time of their last completed follow-up contact. These analyses were not pre-
specified in the IRIS research protocol or data analysis plan. Rather, these analyses were 
designed after completion of the IRIS trial to test the widely accepted (but never substantiated) 
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hypothesis that smoking cessation after stroke improves outcome. This hypothesis was 
strengthened by observational research showing that smoking cessation in patients with 
established coronary heart disease reduces subsequent all-cause mortality22 and recurrent 
cardiovascular events.4,24  
 
All analyses were conducted using the intention-to treat principle (i.e., according to participants’ 
smoking status (quitter versus continuing smoker) at the time of randomization).  
 
Cumulative probabilities of outcome-free survival over time by smoking status were calculated 
by the method of Kaplan-Meier42 and differences were tested by the log-rank statistic using alpha 
of 0.05 (2-sided). The effect of smoking status on risk was quantified by hazard ratios (with 95% 
confidence intervals) from Cox proportional hazards models43 that included baseline 
cardiovascular risk features and treatment assignment (pioglitazone or placebo). The risk features 
included in the Cox models were those pre-specified as adjustment variables for the IRIS trial, 
plus pioglitazone treatment, and included the following: age, sex, stroke [vs. TIA] as index 
event, prior history of stroke, history of hypertension, history of coronary artery disease, systolic 
blood pressure, and diastolic blood pressure. All adjustment variables were obtained by self-
report from participants, except for type of index event (determined by site investigators) and 
blood pressure (measured at screening blood test). Participants missing information on any of 




Causes of death were tabulated using standard CDC categories44 and differences across smoking 




The study cohort was derived from 3,871 IRIS study participants who were randomized between 
February 2005 and January 2013 (five participants were excluded from the original cohort of 
3,876 because of missing smoking information). At randomization, 1309 participants were 
classified as never smokers, 1490 as former smokers, 450 as quitters since the index event, and 
622 as continuing smokers. The total sample for the primary analysis comprised the 450 quitters 
and 622 continuing smokers. Baseline features for quitters and continuing smokers are displayed 
in Table 4. (Features for all 3,871 IRIS participants with smoking information by smoking status 
are shown in Table 5.) Some baseline differences between the quitters and continuing smokers 
were detected and would be expected to reduce risk for vascular outcomes in quitters compared 
with continuing smokers (i.e., quitters were less likely to report a history of stroke or coronary 
artery disease before the index event, and were more likely to use statin therapy).45,46 Other 
baseline differences would be expected to increase risk in quitters (i.e., quitters were more likely 
to enter with a stroke (vs. TIA) and be assigned to receive placebo).46 On laboratory testing, 
quitters had lower fasting glucose, LDL cholesterol, and triglycerides compared to continuing 
smokers. Among women, quitters had higher HDL cholesterol compared to continuing smokers, 
but this difference was not as large in men. Quitters more often reported being heavy smokers 
(i.e., 20+ cigarettes daily) at the time of the index event (60%) compared to continuing smokers 
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at randomization (27%). However, we do not know if this reflects a true difference between 
quitters and continuing smokers for intensity of smoking at the time of the index event or a 
reduction in smoking (or reported smoking) in the latter group between the event and trial entry. 
The mean reported duration of smoking was 40 years in both groups. A total of 32 participants 
(10 never smokers, 13 former smokers, 5 quitters, 4 continuing smokers did not have complete 
data on the eight specified adjustment features and are excluded from the adjusted analyses; 3 
outcomes were excluded). 
 
Clinical Outcomes  
After a median follow-up of 4.8 years, nonfatal stroke, nonfatal MI, or all-cause death had 
occurred in 60 patients in the quitter group and 121 in the continuing smoking group (5-year risk, 
15.7% vs. 22.6%; adjusted hazard ratio [HR], 0.66; 95% confidence interval [CI], 0.48 to 0.90). 
Among secondary outcomes, there were non-significant reductions in the incidence of stroke, 
myocardial infarction, and cancer during follow-up in quitters compared to continuing smokers 
(Table 6, Figure 1, and Table 7). Death occurred in 23 quitters and 66 continuing smokers (5-
year risk, 6.1% vs 13.1%; adjusted HR 0.49; 95% CI 0.30 to 0.79). Among major causes of 
death, the largest difference was observed for cancer: seven deaths among quitters were 
attributable to cancer compared to 21 among continuing smokers (1.5% vs 3.4%; p-value, 0.07) 
(Table 8). A lower percentage of deaths was also observed among quitters from cerebrovascular 
disease (0.2% vs 1.6%, p-value, 0.03), heart disease (0.7% vs 1.6%; p-value, 0.16), and unknown 




At baseline, quitters were slightly more likely than continuing smokers to achieve their 
preventive health goals: 63% of quitters versus 61% of continuing smokers had a blood pressure 
<140/90 mmHg; 85% of quitters versus 80% of continuing smokers were on statins; and 54% of 
quitters versus 49% of continuing smokers had achieved all three of these preventative health 
goals. However, an identical number of quitters and continuing smokers were on anti-thrombotic 
therapy at baseline (99%). During five years of follow-up, quitters were more likely to meet their 
preventative health goals (Table 9).  
 
Of note, 145 of 450 (32%) quitters reported resuming smoking at one or more annual time points 
during follow-up and 190 of 622 (31%) continuing smokers reported having quit.  
 
DISCUSSION 
The results of this study suggest that quitting smoking within six months after an ischemic stroke 
or TIA will significantly reduce the likelihood of nonfatal stroke, nonfatal MI, or all-cause death 
in the next 4.8 years. The observed relative risk reduction (RRR) (34%) and absolute risk 
reduction (ARR) (6.9%) are comparable to other medical treatments for secondary prevention 
after stroke, including antiplatelet therapy,47 statin therapy,45 blood pressure reduction,48 and 
pioglitazone.5 Different outcome measures among secondary prevention studies make strict 
comparison impossible. However, reports suggest that aspirin reduces risk of stroke or death by 
31%,47 high dose statin therapy reduces major cardiovascular events by 20%,45 blood pressure 
lowering therapy with perindopril and indapamide reduces stroke risk by 43%,48 and 
pioglitazone reduces risk for stroke or MI by 26%.5 Anticoagulation for atrial fibrillation stands 
out as a medical treatment for secondary prevention with a substantially greater RRR of 64%, 
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and a comparable ARR of 8%.49 The present study not only supports current guidelines for 
smoking cessation after stroke or TIA,19 but also suggests that cessation may be one of the most 
important single interventions for smokers with an ischemic stroke or TIA.  
  
We are aware of only one other study that has examined the effect of smoking cessation 
immediately after stroke. This observational study of 105 quitters and 135 continuing smokers 
with cerebrovascular disease observed a non-significant reduction in mortality over 14 months in 
quitters compared to continuing smokers.21 By contrast, our study looked at 450 quitters and 622 
continuing smokers over 4.8 years and had more power to detect a difference in outcome 
between quitters and continuing smokers. Other studies have classified smoking status at the 
time of the stroke event and were not designed to examine the effect of quitting.50-52 There have 
been no clinical trials of smoking cessation after stroke or TIA. 
  
We found that the benefit of smoking cessation emerged early (i.e., within 5 years) after an acute 
ischemic stroke or TIA, which is consistent with prior research on the vascular effects of 
smoking. Smoking is thought to increase the risk for vascular disease by two major mechanisms: 
(1) induction of a pro-coagulant state, and (2) acceleration of atherosclerosis.53 The pro-
coagulant state is characterized by an increase in platelet aggregation, increased fibrinogen 
concentration, decrease in fibrinolysis, polycythemia, and high blood viscosity,53 and is rapidly 
reversible within days of smoking cessation.54 Smoking accelerates atherosclerosis through 
several pathways, including impaired endothelial function (with decreases in nitric oxide), 
increased inflammation (through an increase in peripheral leukocytes and inflammatory 
markers), and lipid modification (increased cholesterol, triglycerides, and low density 
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lipoprotein, decreased HDL, and oxidation of LDL).53 Although the atherogenic effects of 
smoking likely take longer to dissipate, several studies have observed that stroke risk declines 
exponentially after smoking cessation and returns to baseline risk within 5 years of quitting.8,55  
  
Smoking cessation in our study had a particularly large effect on all-cause mortality (RRR, 51%, 
ARR, 7.0%). This finding suggests that smoking cessation may be distinct from other medical 
interventions for secondary stroke prevention, which are not associated with significant 
improvement in survival despite reductions in risk for cardiovascular events.5,45,48,49 The one 
exception is antiplatelet therapy after a TIA or stroke, which results in a smaller but still 
significant decrease in risk for all-cause mortality after 3 years of therapy (RRR 12%, ARR, 
1.5%).56 
  
The most common cause of death among IRIS participants was cancer, followed by stroke, heart 
disease, and respiratory infection. All these causes were reduced among quitters, but only 
reached or approached statistical significance for stroke (p=0.03) and cancer (p=0.07). The 
decreased rate of cancer death observed in quitters compared to continuing smokers is most 
likely attributable to the beneficial effects of smoking cessation on case fatality. At baseline, 
quitters and continuing smokers had similar reported cancer histories and similar years of 
exposure to tobacco. Quitters were slightly less likely to be diagnosed with cancer during five 
years of follow-up, but this difference was small and not statistically significant. However, we 
observed a quantitatively large reduction in cancer case fatality in quitters compared with 
continuing smokers (7/31=23% vs 21/49=43%; Chi square p-value, 0.06). The finding that 
quitters have lower rates of cancer death relative to continuing smokers is consistent with other 
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research showing that smoking cessation in patients who already have a cancer diagnosis is 
associated with a rapid decrease in case fatality.57,58 Mechanisms for the rapid decrease may 
include enhanced sensitivity to radiation therapy59 and chemotherapy,60 elimination of 
stimulation of tumor growth by nicotine,61,62 and prevention of death among cancer patients from 
comorbid pulmonary and cardiovascular disease.63,64 
  
The results of this study should be considered in the context of three potential sources of bias. 
Prevention bias refers to the tendency of individuals who make one healthy choice (e.g., quitting 
smoking) to make others as well (e.g., taking medication as prescribed, seeing a doctor regularly, 
exercising) that could improve outcomes.65 Consistent with a prevention bias, quitters in this 
study were slightly more likely than continuing smokers to have achieved their preventative 
health goals at baseline and during follow-up (Table 9). This small difference between groups 
may have increased the benefit attributed to smoking cessation in this study, but is probably not 
large enough to account for the full difference in outcome rates. A second source of bias may 
have resulted from selective loss of patients from the study cohort between the index event and 
randomization. If patients who quit smoking after their stroke/TIA and patients who continued to 
smoke had differing short-term survival or differentially agreed to participate in IRIS based on 
features associated with prognosis, the randomized patients may not reflect the true association 
between smoking and outcomes in the underlying population. A third source of potential bias 
may have resulted from crossover between groups. Since 32% of quitters resumed smoking at 
one or more time points after randomization, and 31% of continuing smokers quit at one or more 
time points after randomization, our results may have been biased toward the null. This suggests 
that magnitude of the benefit from quitting smoking may be even greater than our estimate. In 
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addition to these potential sources of bias, this analysis on smoking was an unplanned, secondary 
analysis of data from a randomized clinical trial and the findings, although compelling, must be 
regarded as hypothesis-generating only. Finally, the IRIS trial enrolled insulin-resistant, non-
diabetic patients and our results may not be generalizable to all stroke patients who smoke. 
  
This study also had several notable strengths, including detailed data on smoking, close follow-
up of participants, and careful adjudication of outcomes. In addition, quitters and continuing 
smokers were well balanced in most demographic and clinical characteristics, specifically 
smoking history, age, and medical comorbidities.  
 
The smoker's paradox 
Other researchers have looked at the relationship between smoking at the time of a coronary 
event or stroke and risk for various outcomes. One surprisingly well-replicated finding among 
studies in both groups of patients is the "smoker's paradox." The smoker's paradox describes the 
counterintuitive observation that smokers have better outcomes (improved survival) than non-
smokers after an acute coronary event66-69 or acute ischemic stroke.70 This paradox may cause 
patients and clinicians to underestimate the adverse effect of a smoking once clinical disease is 
evident. The paradox, however, is not due to a beneficial effect of smoking, but rather to bias.  
 
Index event bias 
"Index event bias," also called "collider stratification bias"71,72 explains why established risk 
factors for an index event (such as stroke) may not appear to be a risk factor for a recurrence of 
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that event.71 Index event bias occurs when a study population is chosen on the basis of a common 
effect (e.g., stroke) of two or more factors (e.g., smoking, hypertension, etc.). Under these 
conditions, the correlation between the risk factor of interest (i.e., smoking) and the disease (i.e., 
stroke) are biased toward the null. The risk factor of interest may even appear to be negatively 
correlated with the outcome of interest.73 A mathematical model of index event bias 
demonstrates that selection based on an index event can create a spurious negative correlation 
between the risk factors for the index event and recurrence of the index event. Such a negative 
correlation does not require any biological connection between the risk factor and outcome, and 
is purely an artifact.73 
 
Examples of index event bias can be drawn from literature on cardiovascular disease, rheumatic 
disease, and birth outcomes. The thrombophilia paradox describes the observation that 
individuals with thrombophilias are at increased risk for a first deep venous thrombosis, but not 
for recurrence.74 The obesity paradox describes the observation that obesity is an established risk 
factor for coronary artery disease, but is protective against recurrent coronary events.75 A patent 
foramen ovale is a risk factor for an initial cryptogenic stroke, but not for recurrent stroke.76 In 
rheumatic disease, many risk factors (e.g., obesity and smoking) for incident osteoarthritis, 
rheumatoid arthritis, or psoriatic arthritis appear to be neutral or protective when used to predict 
disease progression.77 Finally, the birth weight paradox describes the observation that low birth 
weight babies born to mothers who smoke have improved survival.78 
 
The mechanism underlying index event bias can be explained by measured and unmeasured risk 
factors in a population selected on the basis of a known disease. Most studies on coronary artery 
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disease and stroke have categorized smoking at the time of the vascular event. Based on this 
categorization, important differences are observed between "smoking" and "non-smoking" 
groups. In general, smokers with a first vascular event tend to be younger, have fewer 
atherosclerotic risk factors, and fewer medical comorbidities that increase risk for stroke and MI, 
such as diabetes and hypertension.79 Aside from the unhealthy habit of smoking, smokers with a 
vascular event tend to be measurably healthier than nonsmokers with a vascular event. These 
smokers would likely have been spared a vascular event if they had been nonsmokers. The 
underlying better health of smokers explains why they have a better prognosis than nonsmokers 
after a vascular event. 
 
While measurable demographic and clinical differences between smokers and nonsmokers may 
contribute to the observation of a smoker's paradox,79 some studies that control for these 
measurable risk factors still document a residual benefit of smoking.67,69 This residual benefit 
may be explained by differences in unmeasured risk factors between smokers and nonsmokers. 
On average, individuals with a known risk factor (such as smoking) who have an index event 
(such as stroke) tend to have fewer unmeasured risk factors than individuals without known risk 
factors who also have an index event. One example of this phenomenon is observed in low 
birthweight babies. It has been observed, paradoxically, that low birthweight babies whose 
mothers smoke have better outcomes than low birthweight babies whose mothers don't smoke. 
This is because low birthweight babies whose mothers smoke tend have fewer unmeasured risk 
factors for low birthweight, while low birthweight babies whose mothers don't smoke have some 
other, more lethal, etiology for low birthweight (e.g., a genetic syndrome). This effect can be 




Further evidence that index event bias creates a spurious negative correlation between risk 
factors and recurrence comes from intervention studies demonstrating that modifying risk factors 
can improve outcomes. Intervention studies have demonstrated that treating hypertension has 
strong beneficial effects on stroke recurrence.80,81 PFO closure in patients with cryptogenic 
stroke prevents recurrent stroke.82 In the present study, smoking cessation reduced risk for the 
combined outcome of stroke, MI, or death. 
 
One important question is why didn't index event bias obscure the relationship we observed 
between smoking (versus not smoking) and stroke, MI, or death? Since the participants in the 
IRIS trial were selected on the basis of their index event, we might expect that the relationship 
between known risk factors (i.e., smoking) and the outcome to be biased toward the null. 
However, all participants in the primary analysis were smokers at the time of their stroke. 
Although our analysis was a prospective cohort study, not a randomized clinical trial, the 
"intervention," which was smoking cessation, was not differentially related to other vascular risk 
factors in quitters and continuing smokers.   
 
Although it was not the aim of our study to look for a smoker's paradox (or index event bias), a 
comparison of patients who smoked at the time of their IRIS index event with patients who were 
not smoking at that time reveals no evidence for a smoker's paradox (Table 10). Unadjusted 
analyses reveal that nonsmokers at the time of their index event had significantly lower rates of 
nonfatal stroke, nonfatal MI, or death than nonsmokers (5-year risk, 16.1% vs. 19.7%; 
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unadjusted HR 0.80; 95% CI 0.67, 0.95). After adjusting for eight prespecified adjustment 
variables, this difference is even more apparent (adjusted HR 0.57; 95% CI 0.47, 0.69). Although 
we did not observe the smokers’ paradox in the present study, index event bias is a potentially 
important issue in stroke recurrence studies. Researchers interested in the relationship between 
smoking and stroke recurrence should be aware of the index event bias to correctly interpret both 
past and future studies.  
 
Message for patients 
Among 100 patients who continue to smoke after an ischemic stroke or TIA, 23 may be expected 
to have a stroke, MI, or death within 5 years compared to only 16 out of 100 who quit. In simple 
terms, for every 100 of these patients who manage to quit cigarettes, fully 7 additional will 
survive 5 years without MI or recurrent stroke than otherwise would have. 
 
Conclusion 
Healthcare providers have a unique opportunity to counsel patients after they suffer an ischemic 
stroke or TIA. A stroke or TIA can act as a wake-up call for patients, and enhance motivation to 
make lifestyle changes that could prevent a recurrence. This paper provides a quantitative 
estimate for the benefits of smoking cessation in this population. Our results suggest that health 
care providers should give very high priority to helping patients quit smoking cigarettes after an 
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Table 1. Final inclusion and exclusion criteria for the IRIS trial 
Inclusion criteria 
Ischemic stroke or TIA within 6 months of randomization 
Insulin resistance as defined by HOMA-IR >3.0 
Age >= 40 years at randomization 
Ability and willingness to provide informed consent 
 
Exclusion criteria 
Stroke or TIA related to structural cardiac lesion 
Stroke related to head trauma, proximal arterial dissection, or medical procedures 
Diabetes mellitus 
CHF (NYHA class 1-4) or history of CHF 
History of bladder cancer or high risk for bladder cancer 
Active liver disease 
Inability to participate in follow-up activities 
Irreversible medical condition with predicted survival < 4 years 
Oral or patch estrogen contraceptive use 
Ongoing use of oral corticosteroids 
History of intolerance to a TZD 
Pregnancy, desire to become pregnant, or currently breastfeeding 
Current participation in conflicting clinical trial 
ALT > 2.5 upper limit of normal 
Hemoglobin <8.5 g/dL 
Moderate-to-severe pitting edema of feet or legs 
Carotid surgery or carotid stenting procedure within 14 days of randomization 





Table 2. Timetable of assessments 
    M    
 Screening Baseline Wk 2,4,6,8,10,12 4 8 12 Q4M Q12M Exit 
Physical examination X     X  X X 
Medical history X X        
Blood test          
   Hemoglobin X         
   HbA1c X         
   Alanine 
aminotransferase 
X     X  X X 
   Fasting glucose X     X  X X 
   Fasting lipid profile X     X  X  
   Fasting insulin X     X    
   HS C-reactive 
protein 
X     X    
NIH Stroke Scale  X        
Medication inventory  X    X  X X 
Modified mini-
mental examination 
 X    X  X X 
Lifestyle survey  X    X  X X 
Safety and outcome 
screening 
  X   X X X X 
Study medication 
dose changes 
  4 and 8 weeks X X X    
Study medication 
resupply 
  12 weeks  X X X X X 






Table 3. Outcomes For The IRIS Trial Compared With Outcomes For The Student’s Thesis 
Main Study (IRIS trial) Student’s Thesis 
Primary Outcome Primary Outcome 
   Fatal or nonfatal stroke or fatal or non-fatal MI Non-fatal stroke, non-fatal MI, or all-cause mortality 
Secondary outcomes Secondary outcomes 
   Stroke (fatal or non-fatal) Stroke (fatal or non-fatal) 
   Acute coronary syndrome (MI or unstable angina) MI (fatal or non-fatal) 
   Diabetes onset All-cause mortality 
   Cognitive decline  
   Stroke, MI, or severe CHF  







Table 4. Baseline Features by Smoking Status at Randomization 
Feature Continuing (n=622) 
Quitter 
(n=450) 
Demographic features    
  Age, mean (SD), years 58 (9) 58 (8) 
  Male sex, no. (%) 410 (66)  295 (66) 
  Black race, no. (%) 120 (20)  61 (14)  
  Hispanic ethnic group, no. (%) 23 (4)  18 (4)  
Clinical history, no. (%)     
  Stroke at entry (vs TIA) 533 (86) 416 (93)  
  Prior stroke (before index event) 85 (14)  41 (9)  
  Hypertension 453 (73) 310 (69)  
  Coronary artery diseasea 88 (14)  38 (8)  
  Atrial fibrillation 15 (2)  17 (4)  
  Modified Rankin score 3+ 36 (6)  57 (13)  
  Cancer (non-skin) history 26 (4)  20 (4)  
Physical examination    
  Body mass index, mean (SD), kg/m2 30 (6)  30 (5)  
  Abdominal obesityb, no. (%) 362 (59)  285 (64)  
  Systolic blood pressure, mean (SD), mmHg 133 (18)  134 (18)  
  Diastolic blood pressure, mean (SD), mmHg 81 (11)  81 (11)  
Laboratory data, mean (SD)    
  Fasting glucose, mg/dL 99 (10)  97 (10) 
  HOMA-IR  5.6 (2.8)  5.6 (3.1) 
  HbA1c, % 5.9 (0.4)  5.8 (0.4) 
  LDL cholesterol, mg/dL 93 (33)  90 (32) 
  HDL cholesterol-men, mg/dL 42 (11)  43 (10) 
  HDL cholesterol-women, mg/dL 49 (13)  54 (14) 
  Triglycerides, mg/dL 154 (82)  144 (63) 
Concomitant medications, no. (%)    
  Statin 496 (80)  378 (85) 
  Antithrombotic 616 (99)  445 (99) 
  Angiotensin II Receptor Blocker 61 (10)  50 (11) 
  Beta-blocker 197 (32)  113 (25) 
  Thiazide diuretic 164 (26)  107 (24) 
Assigned to pioglitazone, no. (%) 323 (52)  215 (48) 
Cigarettes/day on average, no. (%)   
  20± 168 (27)  269 (60) 
  10-19 205 (33)  117 (26) 
  <10 243 (39)  59 (13) 
  Uncertain 6 (1)   5 (1) 
Duration of smoking, mean (SD), years 40 (11)  40 (10) 
SI conversions:  mg/dL to mmol/L: glucose, multiply by 0.0555; cholesterol, multiply by 0.0259; 
triglycerides, multiply by 0.0113; HbA1c % to mmol/mol: multiply by 10.93 and subtract 23.5 from product.  
aHistory of hospitalization for MI, coronary artery bypass graft, angioplasty or stenting. 




Number of participants with missing data (continuing; quitter): Black race (7; 9); Hispanic ethnic group (1; 
4); stroke at entry (2; 1); prior stroke (0; 1); atrial fibrillation (0; 1); body mass index (2; 2); blood pressure 









Table 5. Baseline Features by Smoking Status at Randomization 
Feature 
Continuing Quitter Former Never 
n=622 n=450 n=1490 n=1309 
Demographic features          
  Age, mean (SD), years 58 (9) 58 (8) 66 (10) 63 (11) 
  Male sex, no. (%) 410 (66) 295 (66) 1083 (73) 747 (57) 
  Black race, no. (%) 120 (20) 61 (14) 122 (8) 139 (11) 
  Hispanic ethnic group, no. (%) 23 (4) 18 (4) 51 (3) 55 (4) 
Clinical history, no. (%)             
  Stroke at entry (vs TIA) 533 (86) 416 (93) 1274 (86) 1148 (88) 
  Prior stroke (before index event) 85 (14) 41 (9) 206 (14) 156 (12) 
  Hypertension 453 (73) 310 (69) 1078 (72) 927 (71) 
  Coronary artery diseasea 88 (14) 38 (8) 216 (14) 119 (9) 
  Atrial fibrillation 15 (2) 17 (4) 123 (8) 109 (8) 
  Modified Rankin score 3+ 36 (6) 57 (13) 113 (8) 117 (9) 
  Cancer (non-skin) history 26 (4) 20 (4) 132 (9) 95 (7) 
Physical examination             
  Body mass index, mean (SD), kg/m2 30 (6) 30 (5) 30 (5) 30 (5) 
  Abdominal obesityb, no. (%) 362 (59) 285 (64) 923 (62) 811 (63) 
  Systolic blood pressure, mean (SD), mmHg 133 (18) 134 (18) 133 (17) 133 (17) 
  Diastolic blood pressure, mean (SD), mmHg 81 (11) 81 (11) 78 (11) 79 (10) 
Laboratory data, mean (SD)           
  Fasting glucose, mg/dL 99 (10) 97 (10) 99 (10) 98 (10) 
  HOMA-IR  5.6 (2.8) 5.6 (3.1) 5.5 (2.7) 5.3 (2.5) 
  HbA1c, % 5.9 (0.4) 5.8 (0.4) 5.8 (0.4) 5.8 (0.4) 
  LDL cholesterol, mg/dL 93 (33) 90 (32) 86 (30) 87 (31) 
  HDL cholesterol-men, mg/dL 42 (11) 43 (10) 45 (12) 44 (11) 
  HDL cholesterol-women, mg/dL 49 (13) 54 (14) 55 (13) 53 (13) 
  Triglycerides, mg/dL 154 (82) 144 (63) 138 (71) 137 (73) 
Concomitant medications, no. (%)            
  Statin 496 (80) 378 (85) 1239 (83) 1071 (82) 
  Antithrombotic 616 (99) 445 (99) 1477 (99) 1292 (99) 
  Angiotensin II Receptor Blocker 61 (10) 50 (11) 241 (16) 194 (15) 
  Beta-blocker 197 (32) 113 (25) 509 (34) 409 (31) 
  Thiazide diuretic 164 (26) 107 (24) 403 (27) 346 (26) 
Assigned to pioglitazone, no. (%) 323 (52) 215 (48) 762 (51) 636 (49) 
Cigarettes/day on average, no. (%)         
  20± 168 (27) 269 (60) 825 (55)   
  10-19 205 (33) 117 (26) 304 (20)   
  <10 243 (39) 59 (13) 305 (20)   
  Uncertain 6 (1) 5 (1) 56 (4)   
Duration of smoking, mean (SD), years 40 (11) 40 (10) 26 (15)   
SI conversions:  mg/dL to mmol/L: glucose, multiply by 0.0555; cholesterol, multiply by 0.0259; triglycerides, multiply by 




aHistory of hospitalization for MI, coronary artery bypass graft, angioplasty or stenting. 








Table 6. Risk of Outcomes by Smoking Status at Randomization 
 
Outcome 





(95% CI) P 
Hazard Ratio 
(95% CI) P 




  or death 
60 15.7% 121 22.6% -6.9% 0.66  (0.49, 0.90) 0.009 0.66  (0.48, 0.90) 0.009 
Nonfatal 
stroke 
31 7.8% 61 10.9% -3.1% 0.68  (0.44, 1.05) 0.08 0.67  (0.43, 1.04) 0.07 
Nonfatal MI 14 4.4% 28 5.9% -1.5% 0.67  (0.35, 1.28) 0.23 0.74  (0.39, 1.42) 0.37 
Death 23 6.1% 66 13.1% -7.0% 0.47  (0.29, 0.76) 0.002 0.49  (0.30, 0.79) 0.004 
Cancerd 31 8.7% 49 10.0% -1.3% 0.86  (0.55, 1.35) 0.52 0.87  (0.55, 1.37) 0.56 
aNumber of participants with event. 
b5-year risk from life-table. 
cAdjusted for 8 pre-specified features (age, sex, stroke [vs. TIA] as index event, prior history of stroke, history of 














Pts. Pts w/ Event 
5-Year 
Risk 
 Cox Models 
  Unadjusted  Adjusteda 
  HR (95% CI) P  HR (95% CI) P 
 
Stroke, MI or Death 
Continuing  622 121 22.6%  Reference  
Quitter  450 60 15.7%  0.66  (0.49, 0.90) 0.009  0.66  (0.48, 0.90) 0.009 
Former  1490 244 18.6%  0.80  (0.64, 0.99) 0.04  0.54  (0.43, 0.68) <.0001 
Never  1309 153 13.3%  0.55  (0.44, 0.70) <.0001  0.43  (0.33, 0.55) <.0001 
 
Stroke 
Continuing  622 61 10.9%  Reference  
Quitter  450 31 7.8%  0.68  (0.44, 1.05) 0.08  0.67  (0.43, 1.04) 0.07 
Former  1490 100 7.8%  0.65  (0.47, 0.89) 0.008  0.49  (0.35, 0.69) <.0001 
Never  1309 89 7.7%  0.65  (0.47, 0.90) 0.009  0.54  (0.38, 0.76) 0.0004 
 
MI 
Continuing  622 28 5.9%  Reference  
Quitter  450 14 4.4%  0.67  (0.35, 1.28) 0.23  0.74  (0.39, 1.42) 0.37 
Former  1490 66 5.4%  0.95  (0.61, 1.48) 0.82  0.76  (0.47, 1.22) 0.25 
Never  1309 36 3.1%  0.57  (0.35, 0.93) 0.03  0.51  (0.30, 0.86) 0.01 
 
Death 
Continuing  622 66 13.1%  Reference  
Quitter  450 23 6.1%  0.47  (0.29, 0.76) 0.002  0.49  (0.30, 0.79) 0.004 
Former  1490 131 10.4%  0.80  (0.59, 1.07) 0.13  0.39  (0.28, 0.53) <.0001 
Never  1309 62 5.6%  0.42  (0.30, 0.59) <.0001  0.25  (0.17, 0.36) <.0001 
           







Table 8.  Causes of Death by Smoking Status at Randomization 
Type Total 
 Continuing Quitter 
Pa 
Former Never 
 n=622 n=450 n=1490 n=1309 
 No. % No. % No. % No. % 
Cancerb 70  21 3.4% 7 1.5% 0.07 28 1.9% 14 1.1% 
Lung 18  10  2   3  2  
Colon 5  1  0   2  2  
Brain 4  0  0   4  0  
Pancreatic 3  0  1   2  0  
Bladder 2  1  0   1  0  
Breast 2  2  0   0  0  
Prostate 2  1  0   1  0  
Primary Unknown 8  1  1   4  2  
Other 26  5  3   11  8  
Cerebrovascular disease 37  10 1.6% 1 0.2% 0.03 18 1.2% 8 0.6% 
Heart disease 35  10 1.6% 3 0.7% 0.16 11 0.7% 11 0.8% 
Influenza and pneumonia 12  1 0.2% 0 0.0%  9 0.6% 2 0.2% 
Accidents and self-harm 9  2 0.3% 1 0.2%  5 0.3% 1 0.1% 
Alzheimer's disease 7  0 0.0% 0 0.0%  4 0.3% 3 0.2% 
Chronic lower respiratory 
disease 
7  0 0.0% 0 0.0%  6 0.4% 1 0.1% 
Other 30  4 0.6% 3 0.7%  18 1.2% 5 0.4% 
Unknownc 75  18 2.9% 8 1.8% 0.24 31 2.1% 17 1.3% 
Total 282  66   23   131  62  
aP-value from chi-square test for proportions, continuing smokers vs. quitters. 
bDeaths attributed to cancer with confirming pathology data.  
cIncludes 6 deaths attributed to cancer by review committee without pathology-confirmed cancer during follow-up (2 continuing 





Table 9.  Participants Meeting Preventive Goals by Time in Trial, by Smoking Status at 
Randomization 
Preventive Goal Time in Trial 
Continuing Quitter 
n=622 n=450 








             
BP<140/90 Baseline 380 240 2 0 61% 283 164 3 0 63% 
 Year 1 369 162 72 19 69% 264 127 43 16 68% 
 Year 2 311 154 115 42 67% 239 112 63 36 68% 
 Year 3 266 128 135 93 68% 224 91 66 69 71% 
 Year 4 226 86 129 181 72% 176 80 72 122 69% 
 Year 5 158 64 98 302 71% 126 54 51 219 70% 
             
On Anti-
thrombotic 
Baseline 616 6 0 0 99% 445 5 0 0 99% 
 Year 1 519 27 57 19 95% 387 11 36 16 97% 
 Year 2 481 28 71 42 94% 374 6 34 36 98% 
 Year 3 415 25 89 93 94% 331 11 39 69 97% 
 Year 4 345 16 80 181 96% 281 8 39 122 97% 
 Year 5 250 14 56 302 95% 191 10 30 219 95% 
             
On Statin Baseline 496 123 3 0 80% 378 69 3 0 85% 
 Year 1 423 124 56 19 77% 320 78 36 16 80% 
 Year 2 391 116 73 42 77% 305 74 35 36 80% 
 Year 3 328 113 88 93 74% 273 69 39 69 80% 
 Year 4 273 82 86 181 77% 229 62 37 122 79% 
 Year 5 192 73 55 302 72% 157 45 29 219 78% 
             
All of Above Baseline 302 315 5 0 49% 240 204 6 0 54% 
 Year 1 276 253 74 19 52% 217 173 44 16 56% 
 Year 2 242 222 116 42 52% 192 158 64 36 55% 
 Year 3 198 194 137 93 51% 187 128 66 69 59% 
 Year 4 171 139 131 181 55% 143 113 72 122 56% 
 Year 5 120 102 98 302 54% 103 77 51 219 57% 
            
Non-Smoker Baseline 0 622 0 0 0% 450 0 0 0 100% 
 Year 1 92 458 53 19 17% 307 92 35 16 77% 
 Year 2 101 407 72 42 20% 281 97 36 36 74% 
 Year 3 103 336 90 93 23% 247 97 37 69 72% 
 Year 4 105 253 83 181 29% 205 86 37 122 70% 
 Year 5 78 186 56 302 30% 152 51 28 219 75% 















(95% CI) P 
Hazard Ratio 
(95% CI) P 




  or death 
397 16.1% 181 19.7% -3.6% 0.80  (0.67, 0.95) 0.01 0.57  (0.47, 0.69) <0.001 
Nonfatal 
stroke 
189 7.8% 92 9.6% -1.8% 0.75  (0.59, 0.96) 0.02 0.60  (0.46, 0.78) 0.0002 
Nonfatal MI 102 4.3% 42 5.3% -1.0% 0.89  (0.62, 1.28) 0.54 0.72  (0.49, 1.06) 0.09 
Death 193 8.1% 89 10.2% -2.1% 0.80  (0.62, 1.02) 0.08 0.41  (0.31, 0.54) <0.001 
aNumber of participants with event. 
b5-year risk from life-table. 
cAdjusted for 8 pre-specified features (age, sex, stroke [vs. TIA] as index event, prior history of stroke, history of hypertension, 







Time to Outcome Events 
Figure 1.  Time to Outcome Event, by Smoking Status (Quitter=solid blue line, Continuing 
smoker=dashed red line); A=Stroke, MI or death; B=Stroke; C=Myocardial infarction; D=death 
from any cause. MI = Myocardial infarction. 
